Industry News
Lab Sciences
Top stories summarized by our editors
3/2/2021

Only eight days after acquiring Acorda Therapeutics' manufacturing and packaging operations, Catalent has bought plasmid DNA maker Delphi Genetics. Catalent has been upgrading a facility in Maryland for plasmid DNA production since 2019, and Delphi recently invested in current good manufacturing practice capacity.

3/2/2021

India recently approved 19 applications for domestic manufacturing of drug intermediates and active pharmaceutical ingredients under the Department of Pharmaceuticals' Production Linked Incentive Scheme. Products include dexamethasone; prednisolone; rifampicin; streptomycin; vitamin B1; 1,1-cyclohexanediacetic acid; 2-methyl-5-nitroimidazole; and para-aminophenol.

Full Story:
PharmaBiz (India)
More Summaries:
streptomycin, rifampicin
3/2/2021

Almac Sciences completed a new research and development center for biocatalysis, flow chemistry technologies and peptides, and it is hiring 20 more employees.

Full Story:
Contract Pharma
3/2/2021

US-based cold chain shipping company CSafe opened a hub in Luxembourg in partnership with DB Schenker for cleaning and storage of temperature-controlled containers. CSafe is also opening its third facility in Italy as demand for COVID-19 vaccines has created a booming market for cold storage.

Full Story:
Delano (Luxembourg)
3/2/2021

Microsoft will provide computational services and artificial intelligence in a multiyear drug discovery and development deal with biopharmaceutical company UCB. Objectives include improving the patient experience, learning more about what causes disease, and leveraging data to accelerate drug discovery and clinical development.

Full Story:
FierceBiotech
More Summaries:
UCB
3/2/2021

IT weaknesses in supply chains have enabled data breaches at retailers, medical centers and government agencies worldwide, and every organization with an IT network should learn to manage third-party risks, writes Michael Cobb. Securing the supply chain includes verifying subcontractors', vendors' and partners' compliance with security standards; assessing risks and implementing a governing strategy for access to the organization's internal resources; and performing security awareness training and social engineering assessments.

Full Story:
TechTarget
More Summaries:
Michael Cobb
3/2/2021

Supply chain disruptions caused by the COVID-19 pandemic along with a border dispute have drugmakers in India seeking to reduce their reliance on China for active pharmaceutical ingredients by making their own APIs or working with domestic manufacturers, executives said during a conference. China supplied about half the APIs in India in 2019, and Biocon supply chief Prasad Deshpande said greater independence will require improvements in India's infrastructure and approval processes.

Full Story:
Reuters
3/2/2021

Single-use vials and variable dosing of drugs administered by injection or infusion contribute to waste and rising Medicare costs, write Kavita Patel, a nonresident fellow at the USC-Brookings Schaeffer Initiative for Health Policy, Julie Donohue, chair of the Department of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health, and Edward Shortliffe, chair emeritus in the Department of Biomedical Informatics at Columbia University. The National Academies of Sciences, Engineering, and Medicine recommends that federal agencies, researchers, manufacturers, payers and physicians find ways to reduce inefficiencies throughout the biopharmaceutical supply chain that result in discarded drugs.

3/2/2021

One in 10 household contacts of people who tested positive for COVID-19 later tested positive for the novel coronavirus, according to a study of about 18,000 people in the journal JAMA Network Open. "A 10% transmission rate is actually high by many infectious disease standards, especially if you consider that many of these secondary cases occurred several days after the index case," when infection control measures could be put in place, co-author Dr. Joshua Metlay said.

3/2/2021

Julie Eggington, CEO and co-founder of the Center for Genomic Interpretation at Sandy, Utah, and Megan Garlapow the institution's chief strategy officer, write that greater focus on making clinically useful tests and solving technical accuracy problems would improve diagnostic value and downstream patient care. They recommend that utility metrics and test accuracy be transparent and standardized and that test reimbursements be based on these metrics so that tests with higher values can receive better reimbursement rates.